Amplification of the dihydrofolate reductase gene is a mechanism of acquired resistance to methotrexate in patients with acute lymphoblastic leukemia and is correlated with p53 gene mutations

E. Goker, M. Waltham, A. Kheradpour, T. Trippett, M. Mazumdar, Y. Elisseyeff, B. Schnieders, P. Steinherz, C. Tan, E. Berman, J. R. Bertino

Research output: Contribution to journalArticleResearchpeer-review

119 Citations (Scopus)


Although dihydrofolate reductase (DHFR) gene amplification is a common mechanism of resistance to methotrexate (MTX) in tumor cell lines, with the exception of a few case reports, the incidence of this phenomenon as a mechanism of MTX resistance in the clinic has not been reported. We studied 38 untreated patients and 29 patients in relapse with acute lymphoblastic leukemia (ALL) for gene amplification and p53 gene mutations. Three patients were studied both at diagnosis and at each of two relapses after treatment with MTX. Nine of 29 relapsed patients (31%) had low-level DHFR gene amplification (two to four gene copies) associated with increased levels of DHFR mRNA and enzyme activity. Of significance was a correlation of gene amplification with pS3 mutations in seven of nine relapsed patients (P < .001). Low-level DHFR gene amplification may be an important cause of MTX resistance in ALL and strengthens the concept that mutations in the p53 gene may lead to gene amplification as a consequence of defective cell cycle control.

Original languageEnglish
Pages (from-to)677-684
Number of pages8
Issue number2
Publication statusPublished - 1 Jan 1995
Externally publishedYes

Cite this